Clinical Research Directory
Browse clinical research sites, groups, and studies.
Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
Sponsor: University Hospital, Basel, Switzerland
Summary
This study is to investigate the physiological mechanism of oxytocin system stimulation using 3,4-methylenedioxymethamphetamine (MDMA) as a physiological tool (acute oxytocin releases), not as a medication. This study seeks to test whether the oxytocin response after MDMA administration is different between individuals with autism spectrum disorder and matched healthy controls.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-06
Completion Date
2028-06
Last Updated
2026-04-29
Healthy Volunteers
Yes
Conditions
Interventions
MDMA
MDMA will be prepared as gelatine capsules containing 25 mg of pharmaceutically pure MDMA hydrochloride (Lipomed AG, Arlesheim, Switzerland) and mannitol filler. MDMA will be administered in a single dose of 100 mg (4 capsules of 25 mg MDMA)
Placebo
Placebos will be prepared as identical gelatine capsules containing only mannitol filler.
Locations (1)
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, Switzerland